NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
Bobbie J. Rimel, Danielle Enserro, David P. Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor Backes, Elizabeth Swisher, Matthew Powell, Helen MacKay
Dive into the research topics of 'NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer'. Together they form a unique fingerprint.